Back to journals
Academic Journal

Nature Medicine

9 Papers Indexed in Blossom

Data updated

Research Footprint

Nature Medicine has 9 tracked papers indexed in Blossom (2021–2026) from 110 authors, most often covering Psilocybin, MDMA and Ibogaine, across Safety & Risk Management, Depressive Disorders and PTSD.

Published Papers

Open Accessmeta

An international mega-analysis of psychedelic drug effects on brain circuit function

This mega-analysis integrated 11 resting-state MRI datasets on acute effects of psilocybin, lysergic acid diethylamide, mescaline, N,N-dimethyltryptamine and ayahuasca, and found that psychedelics commonly increased connectivity between higher-order and sensory brain networks. It also found altered links involving the thalamus, caudate, putamen and cerebellum, with only modest and variable reductions within networks.

Published
Journal
Nature Medicine
Authors
Girn, M., Doss, M. K., Roseman, L., Preller, K. H., Palhano-Fontes, F., Pasquini, L., Barrett, F. S., Mallaroni, P., Mason, N. L., Timmermann, C., McCulloch, D. E., Fisher, P. M., Winston, B. S., Moujaes, F., Muller, F., Liechti, M. E., Vollenweider, F. X., Ramaekers, J. G., Kuypers, K., Araujo, D. B., Sporns, O., Siegel, J., Dosenbach, N., Nutt, D. J., Carhart-Harris, R. L., Stamatakis, E. A., Bzdok, D.
Open Accessmeta

An international Delphi consensus for reporting of setting in psychedelic clinical trials

An international four‑round Delphi (89 experts from 17 countries) produced the ReSPCT guidelines: 30 consensus‑rated extra‑pharmacological variables, categorised into physical environment, dosing session procedure, therapeutic framework and subjective experiences. These guidelines provide a new standard to improve the design and reporting of set and setting in psychedelic clinical trials.

Published
Journal
Nature Medicine
Authors
Pronovost-Morgan, C., Greenway, K. T., Roseman, L.
Open Accessindividual

Randomized Placebo-Controlled Phase 2 Study of Extended-Release Ketamine Tablets (R-107) for Treatment-Resistant Depression - the BEDROC Study

In this phase 2 randomised, placebo‑controlled enrichment study, extended‑release oral ketamine tablets (R‑107) given twice weekly maintained antidepressant response in treatment‑resistant depression, with the 180 mg dose producing a significant 13‑week MADRS improvement versus placebo (least‑square mean difference −6.1, P = 0.019). R‑107 was generally well tolerated with minimal blood‑pressure, sedation or dissociation effects, showed a dose–response reduction in relapse rates, and most dosing was performed at home.

Published
Journal
Nature Medicine
Authors
Glue, P., Loo, C., Fam, J., Lane, H. Y., Young, A., Surnam, P.
Open Accessindividual

Magnesium-ibogaine therapy in veterans with traumatic brain injuries

This observational study (n=30) evaluates ibogaine (up to 980mg/70kg) in combination with magnesium (1-2 hours before and 12 hours later) in male Special Operations Forces veterans with predominantly mild traumatic brain injury (mTBI). The study assessed changes in disability, PTSD, depression, and anxiety immediately and one month after treatment using various scales. Results show significant improvements in functioning and psychological symptoms with no serious adverse events.

Published
Journal
Nature Medicine
Authors
Cherian, K. N., Keynan, J. N., Anker, L., Faerman, A., Brown, R. E., Shamma, A., Keynan, O., Coetzee, J. P., Batail, J. M., Phillips, A., Bassa, N. J., Sahlem, G. L., Inzunza, J., Millar, T., Dickinson, J., Rol, C. E., Keller, J., Adamson, M., Kratter, I. H., Williams, N. R.
Paywallindividual

MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial

This multi-site, randomised, double-blind, Phase IIIb trial (n=104) evaluated the efficacy and safety of MDMA-assisted therapy (MDMA-AT) for individuals with moderate to severe PTSD. The study found significant reductions in PTSD severity (CAPS-5 score) and functional impairment (SDS score) for the MDMA-AT group compared to placebo with therapy. Seven participants experienced severe treatment-emergent adverse events, but no deaths or serious adverse events were reported. The treatment was found to be generally well tolerated in a diverse population.

Published
Journal
Nature Medicine
Authors
Mitchell, J., Ot’alora G, M., van der Kolk, B., Shannon, S., Bogenschutz, M. P., Gelfand, Y., Paleos, C., Nicholas, C. R., Quevedo, S., Balliett, B., Hamilton, S., Mithoefer, A. T., Kleiman, S., Parker-Guilbert, K., Tzarfaty, K., Harrison, C., de Boer, A., Doblin, R., Yazar-Klosinski, B.
Paywallindividual

Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study

In this phase 1 open‑label feasibility study of 10 adult female participants with anorexia nervosa (including partial remission), a single 25‑mg dose of synthetic psilocybin delivered with psychological support was feasible, safe and well tolerated. Adverse events were mild and transient, with no clinically significant changes in ECG, vital signs, laboratory tests or suicidality, apart from two transient asymptomatic hypoglycaemic episodes.

Published
Journal
Nature Medicine
Authors
Peck, S. K., Shao, S., Grue, T., Yang, K., Babakanian, A., Trim, J., Finn, D. M., Kaye, W. H.

Quick Facts

Papers Indexed
9
h-Index
653
Open Access
No
Publisher
Nature Portfolio
Country
United Kingdom
Website
Visit